Table 5.
Associations between MetS and known risk factors for progressive IgAGN at the first visit and the progression of IgAGN observed at the second visit
| Variable | OR | 95% CI | p value |
|---|---|---|---|
| Cystatin-C-based estimate | |||
| MetS | 1.9 | 0.6 – 6.0 | 0.258 |
| 24-hour protein excretion | 2.4 | 1.3 – 4.3 | 0.004 |
| Age | 1.0 | 0.9 – 1.1 | 0.08 |
| ACE medication | 0.5 | 0.2 – 1.6 | 0.264 |
| Creatinine-based estimate | |||
| MetS | 1.4 | 0.5 – 4.0 | 0.505 |
| 24-hour protein excretion | 2.4 | 1.4 – 4.2 | 0.003 |
| Age | 1.1 | 1.0 – 1.1 | 0.011 |
| ACE medication | 0.4 | 0.1 – 0.9 | 0.049 |
| eGFR-based estimate | |||
| MetS | 1.9 | 0.6 – 6.1 | 0.273 |
| 24-hour protein excretion | 2.7 | 1.4 – 5.2 | 0.003 |
| Age | 1.1 | 1.0 – 1.1 | 0.005 |
| ACE medication | 0.3 | 0.1 – 0.9 | 0.029 |
Multivariate analysis with all shown variables in the model. The Hosmer-Lemeshow test for goodness of fit had a p value of 0.139 for cystatin-C-based estimate, of 0.899 for creatinine-based estimate, and of 0.869 for eGFR-based estimate.